CRBU.US Caribou Biosciences Inc

Healthcare Biotechnology USA Stocks
0.3619 USD
Close of Nov 14, 2026
0.3600 2.49
Market cap
USD 39.1M
P/E
-
P/B
0.54x
ROE
-132.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRBU.US undervalued?

Graham number

The Graham number of Caribou Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Caribou Biosciences Inc fundamental analysis

No fundamental analysis for Caribou Biosciences Inc yet.

Caribou Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Caribou Biosciences Inc

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or ref…

Full company profile